Models of metastatic prostate cancer: A transgenic perspective

Prostate Cancer and Prostatic Diseases

Volumn 6, Issue 3, 2003, Pages 204-211

  Winter, S F ^a   Cooper, A B ^a   Greenberg, Norman M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Metastasis; Mouse models; Transgenic

Indexed keywords

ANDROGEN; CELL ADHESION MOLECULE; MATRIX METALLOPROTEINASE; TUMOR SUPPRESSOR PROTEIN;

ACCURACY; BIOCHEMISTRY; BONE METASTASIS; CANCER GROWTH; CANCER MODEL; DOG; GENE EXPRESSION PROFILING; GENE TECHNOLOGY; GENETIC ENGINEERING; GENETIC HETEROGENEITY; HUMAN; MALE; MEDICAL LITERATURE; MEDLINE; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT STRAIN; REVIEW; TRANSGENIC MOUSE; TRANSGENICS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 0141725679     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500655     Document Type: Review

References (69)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Zhau HE, Li CL, Chung LW. Establishment of human prostate carcinoma skeletal metastasis models. Cancer 2000; 88(12 Suppl): 2995-3001.
3. Laufer M et al., Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000; 164: 3-9.
4. Culig Z et al., Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-5478.
5. Murillo H et al., Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142: 4795-4805.
6. Wu HC et al., Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994; 57: 406-412.
7. Jungwirth A et al., Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer 1997; 75: 1585-1592.
8. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980; 283: 139-146.
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
10. Bussemakers MJ, Schalken JA. The role of cell adhesion molecules and proteases in tumor invasion and metastasis. World J Urol 1996; 14: 151-156.
11. Fang J et al., Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 2000; 97: 3884-3889.
12. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993; 68: 4-17.
13. Bubendorf L et al., Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578-583.
14. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-573.
15. Yonou H et al., Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001; 61: 2177-2182.
16. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 39: 246-261.
17. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999; 6: 333-347.
18. Olumi AF et al., Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-5011.
19. Lang SH et al., Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. Prostate 1998; 34: 203-213.
20. Rinker-Schaeffer CW, Welch DR, Sokoloff M. Defining the biologic role of genes that regulate prostate cancer metastasis. Curr Opin Urol 2000; 10: 397-401.
21. Ichikawa T, Ichikawa Y, Isaacs JT. Genetic factors and suppression of metastatic ability of prostatic cancer. Cancer Res 1991; 51: 3788-3792.
22. Noordzij MA et al., The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997; 3: 805-815.
23. Freije JM, MacDonald NJ, Steeg PS. Differential gene expression in tumor metastasis: Nm23. Curr Top Microbiol Immunol 1996; 213(Part 2): 215-232.
24. Yoshida BA et al., Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999; 59: 5483-5487.
25. Dong JT et al., KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268: 884-886.
26. Pollard M. Lobund-Wistar rat model of prostate cancer in man. Prostate 1998; 37: 1-4.
27. Pollard M, Luckert PH. Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone. J Natl Cancer Inst 1986; 77: 583-587.
28. Shirai T et al., Sequential observation of rat prostate lesion development induced by 3,2′-dimethyl-4-aminobiphenyl and testosterone. Jpn J Cancer Res 1993; 84: 20-25.
29. Dunning WF. Prostate cancer in the rat. Monogr Natl Cancer Instit 1963; 12: 351-369.
30. Isaacs JT. The R-3327 system of rat prostatic cancers. Urol Oncol 1996; 2: 115-116.
31. Geldof AA, Rao BR. Prostatic tumor (R3327) skeletal metastasis. Prostate 1990; 16: 279-290.
32. Waters DJ et al, Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 1998; 36: 64-67.
33. Galasko CS. Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 1982; 169: 20-27.
34. Waters DJ, Bostwick DG. Prostatic intraepithelial neoplasia occurs spontaneously in the canine prostate. J Urol 1997; 157: 713-716.
35. el-Gabry EA, Halpern EJ, Strup SE, Gomella LG. Imaging prostate cancer: current and future applications. Oncology (Huntingt) 2001; 15: 325-336: discussion 339-342.
36. Rubin SJ et al., Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991; 46: 31-36.
37. Bookstein R et al., Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990; 87: 7762-7766.
38. Gingrich J, Barrios R, Foster B, Greenberg N. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999; 2: 270-275.
39. Gingrich JR et al., Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57: 4687-4691.
40. Foster BA et al., Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57: 3325-3330.
41. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992; 70(1 Suppl): 254-268.
42. Kaplan-Lefko PJ et al., Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003. In press.
43. Masumori N et al., A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001; 61: 2239-2249.
44. di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992; 23: 287-296.
45. Gabril MY et al., Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Therapy 2002; 9: 1589-1599.
46. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994; 91: 11236-11240.
47. Garabedian EM, Roberts LJ, McNevin MS, Gordon JI. Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice. J Biol Chem 1997; 272: 23729-23740.
48. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci USA 1998; 95: 15382-15387.
49. Perez-Stable C et al., Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Lab Invest 1996; 74: 363-373.
50. Perez-Stable C et al., Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res 1997; 57: 900-906.
51. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001; 12(Suppl 2): S141-S144.
52. Krijnen JI et al., Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993; 100: 393-398.
53. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998; 51: 585-589.
54. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995; 26: 167-170.
55. Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 2002; 53: 118-123.
56. Berruti A et al., Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000; 88: 2590-2597.
57. Hoosein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993; 149: 1209-1213.
58. Festuccia C et al., In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer 1998; 75: 418-431.
59. Ishimaru H et al., Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol 2002; 41: 289-296.
60. Tarle M, Ahel MZ, Kovacic K. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res 2002; 22: 2525-2529.
61. Hu Y et al., Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002; 277: 44462-44474.
62. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51(18 Suppl): 5054s-5059s.
63. Lokeshwar BL. MMP inhibition in prostate cancer. Ann NY Acad Sci 1999; 878: 271-289.
64. Shiozaki H et al., E-cadherin mediated adhesion system in cancer cells. Cancer 1996; 77(8 Suppl ): 1605-1613.
65. Umbas R et al., Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54: 3929-3933.
66. Levenson VV, Transue ED, Roninson IB. Internal ribosomal entry site-containing retroviral vectors with green fluorescent protein and drug resistance markers. Hum Gene Ther 1998; 9: 1233-1236.
67. Yang M et al., Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci USA 2000; 97: 1206-1211.
68. Sweeney TJ et al., Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 1999; 96: 12044-12049.
69. MacLaren DC et al., PET imaging of transgene expression. Biol Psychiatry 2000; 48: 337-348.